Results 131 to 138 of about 461 (138)

Aficamten Monotherapy for Hypertrophic Cardiomyopathy. Reply.

The New England journal of medicine
Pablo, Garcia-Pavia, Martin S, Maron, Gregory D, Lewis   +2 more
openaire   +1 more source

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

International Journal of Toxicology
Eva R Chin, Fady I Malik, Michael K Pugsley   +2 more
exaly  

SEQUOIA-HCM: Aficamten effects consistent across regions

Medicom Conference Report HFA 2025
openaire   +1 more source

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [ 14 C]aficamten following single oral dose administration to rats

Xenobiotica
exaly  

SEQUOIA-HCM: Aficamten safe and efficacious for HCM across the globe

Medicom Conference Report HFA 2025
openaire   +1 more source

SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM

Medicom Conference Report HFA 2024
openaire   +1 more source

Aficamten in Hypertrophic Cardiomyopathy: Roots and Branches of SEQUOIA.

Journal of the American College of Cardiology
openaire   +1 more source

Echocardiographic Changes With Aficamten: A Pixel Is Worth 1,024 Bits.

Journal of the American College of Cardiology
openaire   +1 more source